These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39007278)

  • 1. Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy.
    Gong B; Zhang W; Cong W; Gu Y; Ji W; Yin T; Zhou H; Hu H; Zhuang J; Luo Y; Liu Y; Gao J; Yin Y
    Adv Healthc Mater; 2024 Jul; ():e2400149. PubMed ID: 39007278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models.
    Wang W; Zhou Q; Jiang T; Li S; Ye J; Zheng J; Wang X; Liu Y; Deng M; Ke D; Wang Q; Wang Y; Wang JZ
    Theranostics; 2021; 11(11):5279-5295. PubMed ID: 33859747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
    Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
    J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice.
    Yao D; Li T; Yu L; Hu M; He Y; Zhang R; Wu J; Li S; Kuang W; Yang X; Liu G; Xie Y
    Front Pharmacol; 2024; 15():1351792. PubMed ID: 38919259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.
    Iyaswamy A; Wang X; Krishnamoorthi S; Kaliamoorthy V; Sreenivasmurthy SG; Kumar Durairajan SS; Song JX; Tong BC; Zhu Z; Su CF; Liu J; Cheung KH; Lu JH; Tan JQ; Li HW; Wong MS; Li M
    Redox Biol; 2022 May; 51():102280. PubMed ID: 35286997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier.
    Tashima T
    Antibodies (Basel); 2023 Jun; 12(3):. PubMed ID: 37489365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Drug-Carrier" Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly.
    Han G; Bai K; Yang X; Sun C; Ji Y; Zhou J; Zhang H; Ding Y
    Adv Sci (Weinh); 2022 May; 9(14):e2106072. PubMed ID: 35307993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection.
    Ma F; Yang L; Sun Z; Chen J; Rui X; Glass Z; Xu Q
    Sci Adv; 2020 Jul; 6(30):eabb4429. PubMed ID: 32832671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer's disease.
    Gao C; Chu X; Gong W; Zheng J; Xie X; Wang Y; Yang M; Li Z; Gao C; Yang Y
    J Nanobiotechnology; 2020 May; 18(1):71. PubMed ID: 32404183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.
    Inuzuka H; Liu J; Wei W; Rezaeian AH
    Acta Mater Med; 2022; 1(1):24-41. PubMed ID: 35237768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SSK1-Loaded Neurotransmitter-Derived Nanoparticles for Alzheimer's Disease Therapy via Clearance of Senescent Cells.
    Ji W; Zhou H; Liang W; Zhang W; Gong B; Yin T; Chu J; Zhuang J; Zhang J; Luo Y; Liu Y; Gao J; Yin Y
    Small; 2024 Jun; 20(26):e2308574. PubMed ID: 38429234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
    Xin SH; Tan L; Cao X; Yu JT; Tan L
    Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer's disease mice.
    Guo Q; Xu S; Yang P; Wang P; Lu S; Sheng D; Qian K; Cao J; Lu W; Zhang Q
    J Control Release; 2020 Apr; 320():347-362. PubMed ID: 31978446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
    Xie H; Zhang C
    Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease.
    Wang P; Zheng X; Guo Q; Yang P; Pang X; Qian K; Lu W; Zhang Q; Jiang X
    J Control Release; 2018 Jun; 279():220-233. PubMed ID: 29679667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer's Disease.
    Bhatia S; Singh M; Singh T; Singh V
    Neurochem Res; 2023 Jan; 48(1):13-25. PubMed ID: 35987974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM1A-mediated upregulation of METTL3 ameliorates Alzheimer's disease via enhancing autophagic clearance of p-Tau through m6A-dependent regulation of STUB1.
    Tang Z; Cao J; Yao J; Fan X; Zhao J; Zhao M; Duan Q; Han B; Duan S
    Free Radic Biol Med; 2023 Feb; 195():343-358. PubMed ID: 36587923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of Aberrant E3 Ligases Implicated in Alzheimer's Disease and Development of Chemical Tools to Modulate Their Function.
    Potjewyd FM; Axtman AD
    Front Cell Neurosci; 2021; 15():768655. PubMed ID: 34867205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer's Disease.
    Liu X; Hebron ML; Mulki S; Wang C; Lekah E; Ferrante D; Shi W; Kurd-Misto B; Moussa C
    J Alzheimers Dis; 2019; 72(2):425-441. PubMed ID: 31594232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer's Disease.
    Ma TJ; Gao J; Liu Y; Zhuang JH; Yin C; Li P; Mao L; Xu J; Xu YX; Li YP; Zhao ZX; Yin Y
    Mini Rev Med Chem; 2018; 18(12):1035-1046. PubMed ID: 29243575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.